BD Statement on Québec Selection of BD Veritor™ System for Rapid Detection of SARS-CoV-2 for Health Care Workers

Quebéc City, 26 February 2021 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement after the Québec government announced it has selected to use the BD Veritor™ System for Rapid Detection of SARS-CoV-2 to implement a province-wide testing strategy for health care workers.

Greg Miziolek, president of BD-Canada, said: “We applaud the Québec government for unveiling a rapid testing strategy using the BD Veritor™ System for Rapid Detection of SARS-CoV-2 to quickly obtain results for health care workers administering the COVID-19 vaccine, as well as staff, caregivers and visitors to long-term care homes and seniors’ residences. We look forward to collaborating with the Ministry of Health to provide training tools and ongoing support to staff, and Minister Dubé can count on our full cooperation in facilitating the implementation of testing programs for health care workers and those in close contact with the most vulnerable members of our community.”

“The BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay is performed on an easy-to-use, portable instrument that delivers a digital readout of results in approximately 15 minutes, which is critical to turnaround times for COVID-19 diagnostics, because it provides real-time results and enables decision-making while the patient is still on site. The test uses a mid-nasal swab to collect patient samples, which is less invasive for the patient than nasopharyngeal sample collection. The test, which received Health Canada authorization in early October 2020, has been available in the United States since July 2020 through an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA).”

“BD has been on the forefront of the COVID-19 response providing innovative solutions for immunology research, molecular- and antigen-based diagnostics, devices that aid in therapeutics and injection devices for vaccine administration.”

About the BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay has been authorized by Health Canada under Interim Order. This test is only authorized for the duration of the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, unless the authorization is terminated or revoked sooner. The SARS-CoV-2 antigen assay has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com/en-ca or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.